Skip to main content

J.P. MOCZULSKI/j.p. moczulski The Globe and Mail

Cephalon Inc.'s shares fell slightly in pre-market trading a day after the U.S. drug company formally rejected a hostile takeover bid by Canada's Valeant Pharmaceuticals International .

Cephalon's shares were down 87 cents to $76.50 on the Nasdaq before markets opened, but still significantly higher than Valeant's offer.

The company said Valeant's offer "significantly undervalues" the Pennsylvania-based drug developer in a letter to Valeant chief executive officer Michael Pearson.

Story continues below advertisement

The letter, released after the close of markets on Tuesday, said the Cephalon board has concluded that the March 24 offer of $73 (U.S.) per share was "inadequate and not in the best interests of Cephalon's shareholders."

The board also called the timing of the non-binding offer, which values Cephalon at $5.7-billion, "opportunistic."

It said the 30-day average Cephalon share price of $56.74 on which the offer is based, was near the 52-week low for the company's stock.

Report an error
Comments are closed

We have closed comments on this story for legal reasons. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.